The importance of diversity in clinical trials for hepatitis C

Written by Jameson Kowalczyk. Medically reviewed in December 2024 by Megan Burke, MD.

Updated on October 23, 2024

Diversity is important in clinical trials due to genetic, metabolic, social, economic, and cultural factors that contribute to disease outcomes.

Pat, a hepatitis c survivor, shares her thoughts on disparity within the healthcare system.

From representation reflected in specialties of medical professionals, to balance within clinical trials, health equity is an ongoing evolution.

In the past, donated blood was not screened for hepatitis C, and this could have negatively impacted transfusions for sickle cell anemia.

Most people with hepatitis C have no symptoms until the disease has caused serious liver damage. Here’s what you need to know about hep C diagnosis.

What you need to know about hepatitis C and its genotypes